This new initiative of the MDS Foundation is devoted to patients, family members, and other non-professional interested people. In each episode, experts in the field will discuss novel information on MDS, such as new diagnostic techniques, new therapies etc. They will also answer frequently asked questions, which are relevant to many people.
Inside the Hematopathology Lab: How Bone Marrow Biopsies Shape MDS Diagnosis and Classification [MDS Patient & Family Report]
Join host Dr. Nikolaos Papadantonakis for an in-depth conversation with Dr. Sanam Loghavi of The University of Texas MD Anderson Cancer Center. In this episode, we take listeners inside the hematopathology lab to demystify what happens after a bone marrow biopsy is performed.
Dr. Loghavi explains how traditional morphologic assessment is integrated with modern, molecular testing to establish the diagnosis of myelodysplastic syndromes.
5 Apr 2026
Top MDS Updates from ASH 2025: A Conversation with Dr. Valeria Santini [MDS Patient & Family Report]
In this episode,Dr. Valeria Santini, Associate Professor of Hematology at the University of Florence Medical School in Florence, Italy, joins host Dr. Nikolaos Papadantonakis to discuss advances in lower-risk anemia and review important studies in myelodysplastic syndromes from ASH 2025, and what they mean for patients and families.
6 Jan 2026
Allogeneic Stem Cell Transplant for MDS: Advanced Considerations (Part II) [MDS Patient & Family Report]
In this follow-up episode, Dr. Nikolaos Papadantonakis continues the conversation with Dr. Colin Vale from Winship Cancer Institute of Emory University and Dr. Nancy Luna Torres from Moffitt Cancer Center, diving deeper into advanced transplant topics. This episode is ideal for patients and families who want to understand the nuances of transplant care and post-transplant management.
6 Jan 2026
Allogeneic Stem Cell Transplant for MDS: Understanding the Basics (Part I) [MDS Patient & Family Report]
Join host Dr. Nikolaos Papadantonakis as he welcomes Dr. Colin Vale from Winship Cancer Institute of Emory University and Dr. Nancy Luna Torres from Moffitt Cancer Center to discuss the fundamentals of allogeneic hematopoietic stem cell transplantation for MDS patients. Our experts break down complex medical concepts into easy-to-understand language, helping patients make informed decisions about this important treatment option.
26 Sept 2025
EHA 2025 updates [MDS Professional Report]
This episode features Dr. Nikolaos Papadantonakis from the Winship Cancer Institute of Emory University and Dr. Amer Zeidan from the Yale School of Medicine, discussing research on Myelodysplastic Syndromes (MDS) presented at the 2025 European Hematology Association (EHA) Congress in Milan.
25 Feb 2025
ASH 2024: MDS in Focus [MDS Patient & Family Report]
Join Dr. Madanat (UT Southwestern, Texas), Dr. Stahl (Harvard Medical School, Massachusetts), and Dr. Papadantonakis (Emory University, Georgia) as they break down key Myelodysplastic Syndromes (MDS) abstracts from the 2024 American Society of Hematology (ASH) meeting.
Tune in to gain valuable insights and stay informed about the evolving landscape of MDS management.
28 Oct 2024
MDS Highlights of the 2024 European Hematology Association Congress [MDS Patient & Family Report]
Dr. Rena Buckstein and Dr. Moshe Mittelman join Dr. Nikolaos Papadantonakis to discuss key MDS abstracts presented in the 2024 European Hematology Association Congress. Topics covered include anemia and the role of ivosidenib in higher risk MDS.
29 Jul 2024
Introduction to cytogenetics and mutational testing in MDS [MDS Patient & Family Report]
Dr. Nikolaos Papadantonakis discusses cytogenetics and mutational testing in MDS with Dr. Hetty Carraway and Dr. Moshe Mittelman and how they utilize this information in the clinical setting.
30 Apr 2024
Overview of MDS treatments [MDS Patient & Family Report]
In this episode, Dr. Papadantonakis from Winship Cancer Institute of Emory University, Atlanta, US, and Dr. Mittelman, chairman of the MDS Foundation scientific board, discuss the range of treatment options for patients with MDS.
27 Mar 2024
New drugs for anemia of lower-risk MDS [MDS Patient & Family Report]
MDS experts Drs Nikolaos Papadantonakis of Emory, Atlanta, US, and Moshe Mittelman, Tel-Aviv, Israel, discuss new trials presented in the last meeting of the American Society of Hematology (ASH) 2023. They focus on luspatercept, imetelstat and roxodustat.
23 Feb 2024
Commonly asked questions - Part II [MDS Patient & Family Report]
Mrs. Iris Yahal, founder and director of MDS Israel Support Group (Israel MDS Foundation), discusses with Dr. Moshe Mittelman of Tel-Aviv, an MDS expert, several issues that are within the interest of MDS patients and families, including issues related to quality of life and the participation in clinical trials.
26 Jan 2024
Commonly asked questions - Part l [MDS Patient & Family Report]
In this part I of the frequently asked questions episode, Mrs. Iris Yahal, the founder and director of the MDS Israel Support Group (Israel MDS foundation), asks and discusses with Dr. Mittelman, of Tel-Aviv, several topics that are within the interest of patients and families. The questions of MDS as an inherited disease or as a cancer, as well as issues related to patient-physician relationship, are discussed.
25 Dec 2023
Clinical trials – What’s important to know? (Part II) [MDS Patient & Family Report]
Moshe Mittelman, Professor of Medicine and Hematology from Tel-Aviv and chairman, the scientific board of MDS Foundation, interviews Mrs. Noa Goldschmidt, Chief Study Coordinator in Tel-Aviv Sourasky Medical Center, about clinical trials from the perspective of patients and families. They discuss several issues, include the three phases of trial, why the patients benefit from trials and other important points.
19 Nov 2023
Clinical trials – What’s important to know? (Part I) [MDS Patient & Family Report]
In this episode of the MDS-Foundation Podcast Projects – The Patient and Families
Program, Dr. Moshe Mittelman, Chief MDS Center of Excellence, Tel Aviv Sourasky
(Ichilov) Medical Center, Tel-Aviv, and Mrs. Noa Goldshmidt, Chief Study Coordinator
at TASMC, discussing various issues related to clinical trials. The episode is directed
to MDS patients, their families, and all interested parties, with a special focus on
clinical trials for MDS patients. Among other topics, they explain what clinical trials
are, why they are so important, they describe the stages and process of clinical
trials, and explain why patients can benefit from participation in trials. Finally, they
emphasize that patient safety is the prior interest and is highly maintained, and
provide some interesting real-world examples.
1 May 2023
Blood transfusions and quality of life in MDS [MDS Patient & Family Report]
Prof. Rena Buckstein from Toronto, and Prof. Moshe Mittelman from Tel-Aviv discuss the role of blood transfusions and issues related to quality of life in patients with myelodysplastic syndromes (MDS), including reviewing the recent research in the field.
5 Dec 2022
Bone marrow failure disorders in childhood [MDS Patient & Family Report]
Prof. Akiko Shimamura of Harvard Medical School, Boston, a world known expert of pediatric hematology discusses with Prof. Guillermo Sanz ,of Valencia and Prof. Moshe Mittelman, of Tel Aviv, the various aspects of bone marrow failure including childhood MDS, the differences of this medical problem between adults and children, the unique approach to sick kids and the increasing number of promising therapeutic options
28 Sept 2022
Personalized treatment of MDS [MDS Patient & Family Report]
Drs. Rafael Bejar (San Diego) and Moshe Mittelman (Tel Aviv) discuss the trend towards adjusting the appropriate treatment to the particular MDS patient, a trend that is associated with higher rate of successful treatments and less toxicity. They also address several frequently asked questions.
19 Jun 2022
MDS is already in the genetic era [MDS Patient & Family Report]
The first episode of this program, brings a conversation between Prof. Guillermo Sanz from Valencia and Prof. Moshe Mittelman from Tel Aviv, on several issues relevant for patients, families and other stakeholders interested in myelodysplastic syndromes.
First, they discuss the introduction of genetic tests into clinical practice of MDS. These tests found, for example, that at least a third of MDS patients with the TP53 mutation, do not (!) suffer from poor prognosis as previously thought. The new classification that will include genetic testing and will allow more accurate diagnosis leading to more appropriate treatment.
They then answer frequently asked questions: 1) MDS might be considered as cancer, but more important is the progress towards chronicity of the disease allowing many patients prolonged life expectancy with good quality of life. 2) In a reply to another common question: MDS is basically not an inherited disease ! In >90-95%, the disease is acquired.
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
YouTube views
135,165
Score snapshot 15 Sept 2025
Apple Podcasts (US)
5.0 / 5
3 ratings
Spotify
4.0 / 5
1 ratings
Podcast Authority Score: 38 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
17
Social presence
0
YouTube
86
Engagement
60
Contact MDS Patient & Family Report
Guest appearances
Does not typically book guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of MDS Patient & Family Report?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
